Patient safety standards webinar

Learn what's new with the standards, who they're for and how to use them on Thursday9 May at 7–8pm.

Click here to register

Responding to Patient Safety Incidents: Supporting Resources

We've created some tools and resources to help you make the most of the standards. You’ll find information on what to report and where, and case studies and examples of how others have implemented the standards in practice. There’s also useful signposting to resources to help you find out more information.

This page will be updated when needed so make sure you refer to this every time you use the standards.

Remember, you’ll need to use your professional judgement for individual scenarios. 

What patient safety incidents to report and record

Recording and reporting patient safety incidents supports learning. The definition of the term ‘patient safety incidents’ used in this guide can be found in the patient safety standards.

We encourage you to record and report all patient safety incidents as good practice through recognised systems. However, use your professional judgement for individual scenarios. Find out more about using your professional judgment.

You should record patient safety incidents following internal procedures appropriate for the organisation, sector and setting. 

However, you may need to escalate certain patient safety incidents, and report these as appropriate. This may involve duplication. Reporting requirements should be based on internal, local procedures or national requirements. If in doubt, report it.

The following should be determined internally through individual risk assessments and covered in your internal/organisational policies and standard operating procedures (SOPs) appropriate for the organisation and setting.

  • What to record and report, and how
  • When to escalate and report, and where, i.e., to regions/head office/other providers/Trusts/ local NHS organisations/recognised national reporting routes
  • Who is responsible for what, and who can report/record, e.g., superintendent/chief pharmacist are responsible for agreeing the organisational policy and process to ensure regulatory and professional standards are met, and for deciding roles and responsibilities within their teams.

How to deal with patient safety incidents identified by another organisation

Where errors are identified from other organisations, you should follow your own processes and attempt to inform the original organisation of the incident. 

Where to report patient safety incidents 

The table below shows where to report patient safety incidences across England, Scotland, Wales and Northern Ireland (where applicable).

Your internal and local policies should cover exactly who you need to report to for your setting.

You may need to escalate some incidents, i.e., to regions/head office/other providers/Trusts/ local NHS organisations/regulator/Medicines and Healthcare products Regulatory Agency (MHRA). This should be determined locally and individually through risk assessments and covered in your internal SOPs. SOPs could cover processes like how to complete company-mandated reporting systems and how to inform the people you work with (i.e., your immediate team, line manager, medication safety officer (MSO), superintendent/owner, clinical governance lead or local NHS organisation) where relevant.

Some incidents may need to be additionally reported to specific reporting schemes. For further information, see the section on additional reporting.

Who to report to

 

Registered pharmacy or GP practices

NHS hospital or NHS healthcare organisation

Independent sector hospital

Record the following via the MHRA Yellow Card Scheme (MHRA website) or via the Yellow Card app

  • Suspected adverse drug reactions****** from taking medicines and vaccines
  • Adverse incidents involving medical devices
  • Defective and counterfeit products
  • Adverse incidents involving e-cigarettes and their refill containers (e-liquids).You can also report suspected side effects where harm occurs as a result of a medication error.

In England, suspected adverse drug reactions where harm occurs as a result of a medication error are reportable as a Yellow Card or to LFPSE (via LRMS). If reported to the LFPSE, these will be shared with the MHRA. If LFPSE is not available and harm occurs, report using a Yellow Card.

See the MHRA website for further information.

There are specific reporting arrangements for reporting medical device incidents in each of four nations:

England

  • Internal systems and processes*

  • NHS Learn from patient safety events (LFPSE) (via  local risk management systems (LRMS) or direct as appropriate) (NHS England website)

  • Care Quality Commission (CQC)** (CQC website).

  • Internal systems and processes*

  • Private Healthcare Information Network (PHIN)*** (see our data section on the PHIN website)

  • CQC** (CQC website)

  • LFPSE (via LRMS or direct as appropriate) when providing NHS funded care.

Scotland

Local reporting systems with a focus on quality improvement and learning are promoted in Scotland. The Healthcare Improvement Scotland Adverse Events National Framework on the Healthcare Improvement Scotland website provides useful context.

Wales

  • Internal systems and processes*

  • Once for Wales Concerns Management System (NHS Wales website).

  • Internal systems and processes*

  • Once for Wales Concerns Management System (NHS Wales website).

  • Health Inspectorate Wales (HIW) (HIW website).

Northern Ireland

  • Internal systems and processes* and local risk management systems
  • Northern Ireland Adverse Incident Centre (NIAIC) for incidents involving medical devices 

Incidents that meet the criteria of a Serious Adverse Incident (SAI) are currently reported to SPPG in line with regional SAI procedure*****

*Internal systems and processes include following SOPs and event reporting policy within your own organisation.

**Registered providers carrying out regulated activities are to notify CQC when a medicines safety incident/error causes or is related to these statutory notifiable incidents or events; allegation of abuse, death of a person using the service, incident reported to/investigated by the police, serious injury to a person using the service. For further information, see the CQC website on notifications: guidance to providers

***Only Serious Incidents Never Events need to be reported to PHIN.

****Report adverse incidents and near-misses involving medical devices, in vitro diagnostic medical devices and personal protective equipment.

*****A programme to redesign the current SAI Procedure is progressing which could result in changes to the current reporting process. 

******Report all suspected adverse drug reactions that are:

  • Serious, medically significant or result in harm. Serious events are fatal, life-threatening, a congenital abnormality, disabling or incapacitating, or resulting in hospitalisation
  • Associated with newer drugs and vaccines (▼); the most up-to-date list of black triangle medicines is available at: www.mhra.gov.uk/blacktriangle (see newer drugs and vaccines).

If in doubt whether to report a suspected adverse drug reaction, please complete a Yellow Card.

Additional reporting

While all incidents should be reported through recognised national reporting routes (as above) some incidents should also be reported to specific reporting schemes below:

Controlled drugs (CDs)

If CDs are involved, you should also report this to your local CD accountable officer (CDAO) through the NHS controlled drug reporting site. You should also contact your local CDAO, CD local intelligence network (LIN) and CD liaison officer (CDLO) (where appropriate) below:

If an incident such as CD theft, diversions, loss or fraud is a contributory factor that results in a patient safety incident, you should report it as a patient safety incident in addition to the following (where appropriate):

Aseptic preparation services 

The NHS Pharmaceutical Aseptic Services Group (PASG) operate a national scheme (open across the UK) to record errors occurring within aseptic preparation. Registered users can use an online error reporting portal. See the PASG website for further information.  

Unlicensed aseptic units can also refer to the RPS Quality Assurance of Aseptic Preparation Services standards.  

Radiopharmaceuticals 

Adverse reactions and defective radiopharmaceuticals should be reported to the UK Radiopharmacy Group. See The British Nuclear Medicine Society website for further information.

Resources to help you understand the standards 

Here are some signposting links for further reading on patient safety topics. Please note: Access to RPS resources will require member log in.

Standard 1: Reflect

Knowledge and understanding – continuing professional development (CPD) and training

Safety culture and systems – work system-based factors and approaches (or socio-technical systems) 

Standard 2: Be open and honest

Duty of candour

Just culture and psychological safety

Raising concerns 

Communicating and supporting discussions with patients and the public

Standard 3: Review

Investigation and improvement methodologies

Human factors and work system-based factors (or socio-technical systems) 

Safety-I and safety-II

Thematic review

Standard 4: Record and report

Reporting and recording

Standard 5: Act

Standard 6: Share learning

Case studies and examples

Networks and contacts – for support and sharing your learning

Standard 7: Evaluate

Evaluation

Risk management 

Ways to encourage a patient safety culture in the workplace — including a just, open, reporting and learning culture

Getting the culture right is a ‘just culture’. It’s based upon the principles of fairness, quality, transparency, reporting, learning and safety. It’s achieved when just culture principles are embedded into attitudes, behaviours and practices, and the design of legislation, regulation, standards, policies and systems. 

A just culture promotes an open culture (transparency and discussion), a reporting culture (raising concerns) and a learning culture (learning from incidents). It also creates a just and open working environment that is rewarding to work in, fosters professional empowerment, and enhances the quality of service to patients and the patient experience. These cultures support each other to create a safety culture – balancing accountability and learning and leading to improved patient safety. 

A just culture means removing fears, increasing sharing and reporting of concerns, being able to learn from incidents, being able to share lessons learnt (throughout the profession where appropriate) and using this shared learning to reduce the likelihood of similar incidents happening again contributing to better patient safety. Individuals will only report concerns if they feel they will not be victimised and that it is ‘safe’ to report these concerns. 

To provide assurance and confidence, everybody needs to know where they stand. We all have responsibilities for living the culture and embedding the habit. Individuals and organisations can do this through strong leadership and educating people about a just and safe culture. It is a continuous and evolving movement and may take years to achieve. Further information on culture and patient safety incidents can be found in section 2.5.2 in the MEP.

The information below summarises some ways to encourage a just and safety culture in the workplace. However, some suggestions cannot be implemented by those delivering pharmacy services alone and may need help from government, regulators, commissioners of pharmacy services, pharmacy leadership teams, pharmacy employers, NHS organisations, pharmacy and healthcare organisations or patient safety networks. 

Ensure sufficient resources by:

  • Acknowledging human factors principles by employing organisations 
  • Designing and improving reporting, learning and sharing systems to make them as easy as possible for pharmacy teams to use
  • Making use of existing and new technology to improve systems
  • Providing a safe and supportive working environment 
  • Providing adequate staff levels to balance workload and conflicting priorities
  • Providing guidance, training and skills to respond to patient safety incidences, and protected time for this  
  • Providing time for individuals and teams to respond to patient safety incidences  
  • Employing organisations to reduce the risk of incidents occurring by proactively reviewing, identifying and improving system issues and processes.

Ensure sufficient knowledge of anyone delivering pharmacy services or employed within the pharmacy by:

  • Defining roles and responsibilities for responding to patient safety incidents and knowing when and how to escalate – see standards for outcomes and internal SOPs
  • Encouraging and allocating resources for individual reflection and continuous professional development – an incident can be an indication of a learning need
  • Knowing how to use existing improvement methodology and incident investigation tools and templates to analyse incidents
  • Knowing what should be reported – see what patient safety incidents to record and report
  • Knowing what support is available for employees – see networks
  • Knowing what support is available for patients and/or their carers – see networks
  • Knowing where to report incidents – see where to report patient safety incidents.
  • Regularly learning from incidents. 

Sharing the benefits/impact of taking part in all stages of responding to incidents by:

  • Communicating effectively to colleagues by highlighting key messages though personalised communications e.g. emails, social media, face to face
  • Encouraging incident reporting behaviour, e.g., local praise for reporting, recording, sharing, learning and taking action as positive for patient safety 
  • Providing feedback to anyone delivering pharmacy services or employed within the pharmacy to reinforce reporting habits – internal, local and national reporting systems need to be able to provide this
  • Sharing case studies where reporting, sharing, learning and acting has made a positive difference
  • Sharing learning from incidents with local and national MSO networks for dissemination.

Having open and honest conversations by:

  • Supporting colleagues and understanding their behaviours and limitations by actively listening to them 
  • Actively promoting and supporting whistleblowing, reporting, sharing and taking action by employing organisations
  • Creating a supportive culture and encouraging a safety culture and just culture within the organisation/workplace 
  • Discussing new ways of working, and co-designing and producing them with people impacted by the work
  • Discussing proactive actions to manage risk to avoid the same situation in other scenarios or with other medicines
  • Educating the public and general media that encouraging incident reporting improves patient safety, that healthy levels of reporting are positive and show that a pharmacy team is committed to patient safety, that campaigns to encourage reporting will lead to a ‘good’ increase incidents of reporting and that increases in incidents of reporting should be described fairly and within context.
  • Enhancing and managing psychological safety in the workplace when incidents occur to minimise psychological harm
  • Having discussions with teams and providing training at the right time, e.g., during inductions, and refreshing regularly to set expectations
  • Informing teams that a defence to a criminal sanction for inadvertent dispensing errors is implemented, incentivising an increase in the reporting of dispensing errors – see legislation
  • Informing teams that human factors principles are considered by employers and regulators. 

Sharing best practice 

Lead by example. Here are some of your case studies and examples of meeting the standards, good practice and lessons learned.

The General Pharmaceutical Council (GPhC) notable practice for inspection examples:

See GPhC knowledge hub website for further examples.

Controlled drugs diversion on ward – Shalini Gujral, Chief Pharmacist Private Sector

While undertaking the weekly pharmacy top up on the ward, the pharmacy assistant noticed an empty box of dihydrocodeine 30mg tablets and an empty box of diazepam 2mg tablets in the medicine stock cabinet. Both boxes were pristine with no evidence that they had been dispensed from. The drugs could not be located in the medicines cabinet or clinical room. She notified the ward pharmacist who confirmed no patients had been on these drugs for the last month. The Chief Pharmacist and Hospital Director (who is also the CDAO) were notified immediately. The clinical notes of patients attending in the last two weeks were checked, and no diazepam or dihydrocodeine had been prescribed. The incident was recorded on Datix and treated as a diversion. The following external bodies were notified about the diversion: the CD LIN, the CDLO and the Home Office. As part of the investigation, staff with access to the clinical room and drug cupboards were interviewed. These interviews highlighted that drug security in the clinical room on the ward could not be assured at all times, as the drug cabinets were sometimes unlocked. The missing drugs could not be accounted for, but changes were made following this incident, including medicines management and security training for staff and increased security measures of schedule 4 and 5 CDs. Policies were updated and disseminated after this change, so all staff were aware of the new CD requirements. This incident highlighted the importance of reviewing processes following an incident and acting accordingly. A copy of the investigation was provided to the external bodies notified about the incident. 

Prescribing methotrexate 10mg tablets incident – GP practice

Methotrexate (MTX) was prescribed as 10mg tablets, take two tablets 2 weekly (supply of eight tablets). The patient took all eight tablets (80mg) as one dose as they thought they were 2.5mg tablets (what is usually prescribed) despite apparently two pharmacies informing him of the different strength and the pharmacy dispensing the prescriptions reiterating this and informing of the dose change, i.e., two tablets a week. 10mg tablets should not have been prescribed, but the prescription was for the correct dose and direction was issued. 

On realising the problem, the pharmacy was informed. The pharmacy contacted the patient and confirmed they had taken the above dose, and they advised the person to go straight to hospital. The bloods taken in hospital were monitored by the surgery. The patient was contacted to arrange for repeat bloods. The surgery informed the patient’s consultant of the events, who confirmed to withhold MTX for two weeks (the patient was going on holiday so the consultant advised the medication be withheld until their return, as they were going to a sunny location (risk of photosensitivity)). 

What could have been done better?

  • Staff involved in the process to take more diligence and check before overriding computer system warnings and questioning if messages don’t appear correct 
  • The GP could have noticed before signing script
  • Pharmacy A could have returned or highlighted that 10mg were prescribed and queried this to the practice and not given the script to the patient to take to another pharmacy
  • Pharmacy B could have returned or highlighted that 10mg were prescribed and queried this to the practice and not dispensed the prescription.

Reflections on the event

The person who amended the strength from 2.5mg to 10mg after receiving hospital letter to increase the dose was an administrative member of staff. They had undertaken some external learning on DMARD drugs and at no point in the training resource was any issue of prescribing 10mg tablets raised. Review of resources highlighted original National Patient Safety Agency (NPSA) documents on this now on archived gov.org website. BNF states “do not prescribe 10mg tablets” but underneath it, reflects the wording of a current NPSA alert where prescribers are advised “consider the patient's overall polypharmacy burden when deciding which formulation to prescribe, especially in those with a high pill burden”. On discussing with the person that altered the repeat, they stated that they were thinking to reduce the number of tablets but were not aware of the BNF guidance. 

Changes made

The person involved undertook additional training and has themselves done a personal reflective account on this. If printing prescriptions for MTX or any DMARDS, recent blood test results must be printed and attached to the prescription to give the prescriber for added awareness of a high-risk drug and to check thoroughly before signing.

Pauline Lockey Patient Safety Clinical Lead (Medication Safety) NHS England

As a patient safety clinical lead in NHS England’s National Patient Safety Team, a core part of my work is to identify patient safety risks that occur in the delivery of healthcare. Where a risk has been identified, I work with colleagues to develop advice and guidance to support the NHS to take action to address those risks and keep patients safe. I’m part of a wider team that reviews patient safety events recorded by staff and patients on our national systems to identify new or under-recognised patient safety issues. In some cases, an identified new or under-recognised risk will meet the criteria for a National Patient Safety Alert, but where this doesn’t happen, we look to work with partner organisations which may be better placed to take action to address the issue. 

As an example, we identified a report that outlined that a baby required hospital treatment for seizures, following administration of doses of phosphate that were 16 times higher than intended; effervescent phosphate tablets were used to administer the doses of phosphate. Our analysis of reported patient safety events data, identified a number of concerns relating to the use of portions of phosphate or calcium effervescent tablets in children. There were indications that errors occurred at each stage of the medicine journey – prescribing, dispensing, preparation and administration.

There are no licensed oral liquid calcium or phosphate products available in the UK. Administration of a portion of a licensed effervescent calcium or phosphate tablet is common, and such off-label practice is challenging and prone to error. Collaborative working with several partner organisations led to publication of the following resources and delivery of a webinar to the national medication safety officer network: 

Further case studies can be found on the NHS England Patient safety review and response case studies by clinical specialty. These highlight the importance of recording patient safety events and the direct action the National Patient Safety Team takes in response to patient safety events recorded by organisations, staff and the public, and how their actions support the NHS to protect patients from harm. 

Leanne Gurney, Medicines Safety Pharmacy Technician in England

As a Medicines Safety Pharmacy Technician working in an Acute Hospital Trust, I work alongside the MSO. Together, we promote the safer use of medicines, managing medication incidents in the organisation, and improving the reporting and learning from these. We do this by working with multi-disciplinary teams and healthcare professionals. Shared learning across our Trust is promoted in a variety of ways, such as our Medicines Event Review Group, Learning from Events Forum and during quality reviews.
When reviewing our pharmacy incidents, we ensure we take a just culture approach and look at the incident both in detail and systemically. It’s important to understand the psychological impact an error can have on an individual and how it can lower confidence in practice, while valuing professional accountability. We have reflective conversations with our colleagues, ensuring that we handle the conversation constructively and give the individual an opportunity to be open and honest in a safe space, while we in the medicine’s safety team remain professional and empathetic towards them. There are a multitude of factors that contribute towards errors and those that are highlighted, tend to funnel into the environmental factors, such as physical or external influences like tiredness or distractions. We also have our colleagues involved in errors fill out reflective accounts in their own time, sometimes individuals prefer doing this as it gives them more time to think about the situation and any personal circumstance that contributed towards the error that they may not want to divulge during the conversation. 

As pharmacy technicians within the pharmacy team, we can really make an impact to our patient care by being open and honest when errors have occurred. And understanding, through the investigation, the reasons why they happened gives us the opportunity to make our Trust a safer place to work.

A medicines safety alert was issued regarding potassium permanganate soak tablets, which are used to treat skin conditions that blister or weep. They are to be diluted in water and the affected area of skin, soaked in the solution. However, when patients have ingested it orally it has caused death or severe harm even in a hospital setting. The medication safety team liaised with stakeholders for a multidisciplinary approach to review the entire treatment pathway with necessary risk assessments in place. When reviewing systems and processes for safety, it is important to consider removing barriers as well as adding additional steps – a complex process has potential for mistakes or non-adherence.

Share your own examples

We’d love to hear examples of the ways you or your organisation are using the standards in practice.

To support users of the standards, we’re planning to develop the examples you share with us into case studies for the website. 

Share your examples with us by emailing: [email protected].

It will be helpful for you to cover the following points in your examples for us to develop into case studies for the website:

  • Details of your role (job title, type of prescriber and area of practice you work in)
  • Details of your organisation (name and type of organisation)
  • Which standard or supporting statement your example relates to
  • Description of the example (i.e., what is being done, how you demonstrate the standard, any learnings, how you shared the learnings and with who, and any outcome or result).

Further supporting links and resources

Presentation

We’ve made a PowerPoint presentation to help you and your teams use and understand the standards. This will shortly be available for download, but will be presented live by the lead author, with members of the steering committee available to answer any questions you may have.

Register to attend the webinar on Thursday, 9 May at 7–8pm.

National patient safety guidance 

England 

Wales 

Scotland 

Northern Ireland

Regulatory – standards and professional standards

Legislation

Reports and publications